Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag

Biogal Gyogyszergyar Rt.

Corus Pharma, Inc.

Teva Gyogyszergyar Reszvenytarsasag

Plus Chemicals, B.v.

“Avidin” Kutato, Fejleszto Es Kereskedelmi Korlatolt Felelossegu Tarsasag

Ubichem Kutato Korlatolt Felelossegu Tarsasag

Teva Gyógyszergyár Zártkörüen Müködö Részvénytárasaság

Teva Gyógyszergyár Zártkörún Müködö Részvénytársaság

Teva Gyógyszergyár Zárkörüen Müködö Részvénytársaság

Soneas Kutato Korlatolt Felelossegu Tarsasag

Csaba Szabo

Vilmos Keri

Claude Singer

Viktor Gyollai

Judith Aronhime

Lajos Deak

Adrienne Kovacsne-Mezei

Tivadar Tamas

Sandor Janos Molnar

Szabolcs Salyi

Istvan Bodi

Janos Hajko

Erzsebet Meszaros Sos

Edit Arvai Nagyne

Ilona Forgacs

Edit Nagyne Arvai

Lorant Gyuricza

Valerie Niddam-Hildesheim

Greta Sterimbaum

Istvan Barta

Janos Balint

Valeria Szell

Ehud Amir

Ferenc Korodi

Margit Bidlo Nee Igloy

Csilla Nemethne Racz

Antal Kovacs

Gyorgy Toth

Aniko Tegdes

Iiona Forgacs

Laszlo Puskas

Liliana Feher

Zoltan Konyari

Sandor Horkay

SzilaJudit

Laszlo Eszenyi

Ferenc Vinczi

Nelli Sas

Janos Erdelyi

Ilona Himesi

Ivan Kanizsai

Csaba Peto

David Leonov

Erika Magyar Molnarne

Erszebet Meszaros-Sos

Micahel Pinchasov

Szabolcs Szoke

Gabor Tamas

Bela Ozsvari

Ramona Madacsi

Arvai Edit Nagyne

Gyula Jerkovich

IIdiko Lang

Edit Nagy Nee Arvai

Mario Gyuris

Kovacsne-Mezei; Adrienne

The invention relates to compounds of the general formula (I) and their pharmaceutically acceptable salts (in which formula Rrepresents a hydrogen atom, lower alkyl group, lower alkenyl group, lower cycloalkyl group, aryl group, aralkyl group or heterocyclic group, wherein, the above groups are optionally substituted in ortho, meta and/or para position with 1, 2, 3 or 4 electron withdrawing groups or electron donating groups; The compounds according to the invention can be used in the medicine mainly for the treatment of diseases associated with neurological and/or oxidative stress.

8-hydroxy-quinoline derivatives

Processes are provided for preparing mupirocin calcium dihydrate from pseudomonic acid in a two phase system by using an organic carboxylate. A highly pure composition of amorphous mupirocin calcium is provided, and processes for its preparation by solvent removal, lyophilization and precipitation with use of an anti-solvent. Pharmaceutical compositions of amorphous form, and methods of using them to treat infections are also provided. Also provided are combined processes for preparing mupirocin calcium dihydrate and amorphous, by producing amorphous form first, followed by conversion of amorphous form into the dihydrate through crystallization from an aqueous solution. Also provided are processes for removing the water of crystallization of the dihydrate to obtain mupirocin calcium anhydrate.

Processes for preparing crystalline and amorphous mupirocin calcium

The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates.

Production of dolasetron

An amorphous pimecrolimus and processes for providing an amorphous pimecrolimus are provided.

Non-hygroscopic and powdery amorphous pimecrolimus

Provided is a process for preparation of amorphous form of an active pharmaceutical ingredient.

Process for preparation of amorphous form of a drug

The invention relates to the &#x3b2; polymorph of Aztreonam, which contains less than 2.5% by weight residual solvent and to a process of making said polymorph. In the process of the invention, a polymorph of Aztreonam is dissolved in an absolute Calcohol in the presence of a base to form a solution, an acid is added to the solution, and the solution is stirred efficiently.

Aztreonam &#x3b2; polymorph with very low residual solvent content

Provided are crystalline mycophenolate sodium forms and processes for their preparation.

Crystalline mycophenolate sodium

Provided is a method for obtaining a macrolide, especially tacrolimus, from biomatter.

Method for extracting a macrolide from biomatter

The present invention relates to the L-lysine salt of aztreonam and methods for making the L-lysine salt of aztreonam.

Aztreonam L-lysine and methods for the preparation and analysis thereof

The present invention provides a process for the preparation of pimecrolimus from ascomycin in which ascomycin is reacted with a conversion reagent that converts ascomycin to its activated derivative at C-32. The activated ascomycin is then reacted with chloride ion. The process of the invention requires fewer process steps than prior art processes, and does not require the protection of the ascomycin C-24 hydroxyl group or the purification of the activated ascomycin derivative.

Methods of preparing pimecrolimus

Aztreonam L-lysine and methods for the preparation thereof

New polymorphic forms of pravastatin sodium are provided. Each of the new forms is selectively obtained by crystallization from different solvent systems, each solvent system having a protic component, and by controlling the rate of crystallization through temperature. The new polymorphic forms are suitable for use as active substances of pharmaceutical dosage forms for reduction of serum cholesterol levels in the bloodstream.

Forms of pravastatin sodium

The invention relates to a process for the synthesis of Aztreonam. Specifically, the process entails hydrolyzing [3S-[3&#x3b1;(Z),4&#x3b2;]]-3-[[(2-amino-4-thiazolyl)[(1-t-butoxycarbonyl-1-methylethoxy)imino]acetyl]amino]-4-methyl-2-oxo-1-azetidinesulfonic acid (t-Bu Aztreonam) to form Aztreonam.

Preparation of Aztreonam

A process for preparing ondansetron by transamination of an ondansetron structural analog that can be readily prepared conveniently by a Mannich reaction is provided. The process represents an improvement upon known procedures for making ondansetron by transamination because of its rapid rate, selectivity and the ease with which the product can be isolated from the reaction mixture.

Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-YL)methyl]-4H-carbazol-4-one

Growing community of inventors

Debrecen, Hungary

Csaba Szabo